CD86 / B7-2 Antikörper

The B-lymphocyte activation antigen B7-2 (referred to as B70), also known as CD86, is a member of the cell surface immunoglobulin superfamily and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. B7-2 exists predominantly as a monomer on cell surfaces and interacts with two co-stimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus induces the signal pathways which regulate T cell activation and tolerance, cytokine production, and the generation of CTL. Binding of B7-2 with CD28 induces the activation of T cell, whereas CTLA-4 acts as a negative regulator and diminishes the immune responses. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. It is indicated that contacts between B and T helper cells mediated by CD86 encourage signals for the proliferation and IgG secretion of normal B cells and B cell lymphomas. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy.

1. Azuma, M. et al., 1993, Nature. 366: 76-79.
2. Seino, K. et al., 1995, Int. Immunol. 7: 1331-1337.
3. Freeman, G.J. et al., 1993, Science. 262: 909-911.
4. Suvas, S. et al., 2001, J. Biol. Chem. 277: 7766-7775.
5. Bhatia, S. et al., 2005, Proc. Natl. Acad. Sci. 102: 15569-15574.
6. Sigal, L.J. et al., 1998, J. Immunol. 161: 2740-2745.
7. Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.